SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma

Zhao,Wencai; Zhou,Jiancheng; Deng,Zhuo; Gao,Yang; Cheng,Yongyi

doi:10.3892/ijo.2016.3609

SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma

Authors:
- Wencai Zhao
- Jiancheng Zhou
- Zhuo Deng
- Yang Gao
- Yongyi Cheng
View Affiliations

Affiliations: Department of Urology, Shaanxi Provincal People's Hospital, Xi'an, Shaanxi 710068, P.R. China, Department of Gynecology, Shaanxi Provincal People's Hospital, Xi'an, Shaanxi 710068, P.R. China
Published online on: July 6, 2016 https://doi.org/10.3892/ijo.2016.3609
Pages: 1001-1008

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is the most common type of kidney cancer, about one third of the cases are diagnosed at advanced stages with metastases and effective treatments for metastatic RCC are lacking. The molecular events supporting RCC progression remain poorly understood. SPOP, an E3 ubiquitin ligase component, was recently showed to sufficiently promote RCC tumorigenesis, however, other potential functions of SPOP in RCC have not been studied. In the present investigation, by assessing the immunohistochemical staining of SPOP in urological tumors, we found the protein was highly expressed in RCC, in particular, it was specifically expressed in clear cell RCC. cDNA microarray data showed that SPOP mRNA level was significantly increased in clear cell RCC compared to normal kidney tissues, which might be the result of the abnormal DNA copy number of this gene. More interestingly, SPOP was positive in tumors with local invasion or metastasis, and it was associated with tumor recurrence-free survival of clear cell RCC patients. Further in vitro assays demonstrated that SPOP drove RCC epithelial-mesenchymal transition (EMT) and promoted cell invasion. Mechanistically, SPOP enhanced β-catenin protein expression as well as its nuclear translocation, and elevated TCF4 expression. Both β-catenin and TCF4 upregulated the critical EMT-inducing transcription factor ZEB1, which functioned as an effector of β-catenin/TCF4 signaling in RCC invasion. These data identified SPOP as a new marker and prognostic factor for clear cell RCC, and its functions provide new insight into the molecular mechanisms of RCC progression, in which SPOP appears to be an EMT activator.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hollingsworth JM, Miller DC, Daignault S and Hollenbeck BK: Five-year survival after surgical treatment for kidney cancer: A population-based competing risk analysis. Cancer. 109:1763–1768. 2007. View Article : Google Scholar : PubMed/NCBI
3	McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005. View Article : Google Scholar
4	Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, et al: Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 65:1086–1092. 2014. View Article : Google Scholar
5	Koshkin VS and Rini BI: Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 17:1225–1232. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mains PE, Kemphues KJ, Sprunger SA, Sulston IA and Wood WB: Mutations affecting the meiotic and mitotic divisions of the early Caenorhabditis elegans embryo. Genetics. 126:593–605. 1990.PubMed/NCBI
7	Kent D, Bush EW and Hooper JE: Roadkill attenuates Hedgehog responses through degradation of Cubitus interruptus. Development. 133:2001–2010. 2006. View Article : Google Scholar : PubMed/NCBI
8	Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, et al: Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science. 323:1218–1222. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang Q, Zhang L, Wang B, Ou CY, Chien CT and Jiang J: A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev Cell. 10:719–729. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol JH, Baek SH, Chiba T, Tanaka K, Bang OS, et al: BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem. 281:12664–12672. 2006. View Article : Google Scholar : PubMed/NCBI
11	Hernández-Muñoz I, Lund AH, van der Stoop P, Boutsma E, Muijrers I, Verhoeven E, Nusinow DA, Panning B, Marahrens Y and van Lohuizen M: Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA. 102:7635–7640. 2005. View Article : Google Scholar : PubMed/NCBI
12	Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 14:435–446. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, et al: Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
14	Su D, Stamatakis L, Singer EA and Srinivasan R: Renal cell carcinoma: Molecular biology and targeted therapy. Curr Opin Oncol. 26:321–327. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, et al: SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 25:455–468. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, et al: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene. Feb 15–2016.(Epub ahead of print). View Article : Google Scholar
17	Zhou J, Zhu G, Huang J, Li L, Du Y, Gao Y, Wu D, Wang X, Hsieh JT, He D, et al: Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett. 370:313–323. 2016. View Article : Google Scholar
18	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
19	Muglia VF and Prando A: Renal cell carcinoma: Histological classification and correlation with imaging findings. Radiol Bras. 48:166–174. 2015. View Article : Google Scholar : PubMed/NCBI
20	Eggener S: TNM staging for renal cell carcinoma: Time for a new method. Eur Urol. 58:517–519; discussion 519–521. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
23	Tania M, Khan MA and Fu J: Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA. 108:19204–19209. 2011. View Article : Google Scholar
25	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
26	Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, Russo P, Motzer RJ, Reuter VE and Tickoo SK: Carbonic anhydrase IX expression in clear cell renal cell carcinoma: An immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 32:377–382. 2008. View Article : Google Scholar : PubMed/NCBI
27	Hes O, Michal M, Kuroda N, Martignoni G, Brunelli M, Lu Y, Adley BP, Alvarado-Cabrero I and Yang XJ: Vimentin reactivity in renal oncocytoma: Immunohistochemical study of 234 cases. Arch Pathol Lab Med. 131:1782–1788. 2007.PubMed/NCBI
28	Ozcan A, Zhai J, Hamilton C, Shen SS, Ro JY, Krishnan B and Truong LD: PAX-2 in the diagnosis of primary renal tumors: Immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 131:393–404. 2009. View Article : Google Scholar : PubMed/NCBI
29	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
30	Peinado H, Quintanilla M and Cano A: Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. J Biol Chem. 278:21113–21123. 2003. View Article : Google Scholar : PubMed/NCBI
31	Kypta RM and Waxman J: Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012. View Article : Google Scholar : PubMed/NCBI